Ask AI
ProCE Banner Activity

Next-Generation Endocrine Therapies for ER+/HER2- Breast Cancer Care: Key Takeaways From Our Recent Symposium in San Antonio

Clinical Thought

Get up to date with experts’ key takeaways on next-generation endocrine therapies for ER-positive/HER2-negative breast cancer, including guidance on ESR1 mutation testing, use of oral SERDs in patients with ESR1 mutations, and other endocrine therapies on the horizon.

Released: December 20, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Disclosure

Primary Author

Erika Hamilton, MD

Chair, Breast Executive Committee
Director, Breast Cancer Research Program
Sarah Cannon Research Institute
SCRI Oncology Partners
Nashville, Tennessee

Erika Hamilton, MD: researcher (paid to institution): AbbVie, Acerta, Accutar Biotechnology, ADC Therapeutics, AKESOBIO Australia, Amgen, Aravive, ArQule, Artios, Arvinas, AstraZeneca, AtlasMedx, BeiGene, Black Diamond, Bliss BioPharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Cascadian Therapeutics, Clovis, Compugen, Context Therapeutics, Cullinan, Curis, CytomX, Daiichi Sankyo, Dana-Farber Cancer Institute, Dantari, Deciphera, Duality Biologics, eFFECTOR Therapeutics, Eisai, Ellipses, Elucida Oncology, EMD Serono, Fochon, FujiFilm, G1 Therapeutics, Gilead Sciences, H3 Biomedicine, Harpoon, Hutchinson MediPharma, Immunogen, Immunomedics, Incyte, Infinity, Inspirna, InventisBio, Jacobio, Karyopharm, K-Groub Beta, Kind, Leap, Lilly, Loxo Oncology, Lycera, Mabspace Biosciences, MacroGenics, MedImmune, Mersana, Merus, Millennium, Molecular Templates, Myriad Genetic Laboratories, Novartis, Nucana, Olema, OncoMed, Oncothyreon, ORIC Pharmaceuticals, Orinove, Orum, Pfizer, PharmaMar, Pieris, Pionyr Immunotherapeutics, Plexxikon, Prelude, Profound Bio, Radius Health, Regeneron, Relay Therapeutics, Repertoire Immune Medicine, Rgenix, Roche/Genentech, SeaGen, Sermonix, Shattuck, Silverback, StemCentRx, Stemline, Sutro, Syndax, Syros, Taiho, TapImmune, Tesaro, Tolmar, Torque, Treadwell, Verastem, Zenith Epigenetics, Zymeworks; consultant/advisor (paid to institution): Accutar Biotechnology, Arvinas, AstraZeneca, Circle, Daiichi Sankyo, Entos, Gilead Sciences, IQVIA, Janssen, Jazz, Jefferies, Johnson & Johnson, Lilly, Medical Pharma Services, Mersana, Olema, Pfizer, Roche/Genentech, Shorla, Stemline, Tempus Labs, Theratechnologies, Tubulis, Zentalis.

Kevin Kalinsky, MD, MS, FASCO

Professor of Medicine
Louisa and Rand Glenn Family Chair in Breast Cancer Research
Winship Cancer Institute
Emory University
Atlanta, Georgia

Kevin Kalinsky, MD, MS, FASCO: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Genentech/Roche, Gilead, Puma Biotechnology, Seattle Genetics.